Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agios Heads Toward Pivotal Study As FDA Places Hold On Backup

Executive Summary

Biotech’s decision on which candidate to advance to pivotal studies in pyruvate-kinase R deficiency is clarified as backup candidate AG-519 is placed on clinical hold and shelved. Agios hopes to bring the first disease-modifying PKD drug therapy to market.

You may also be interested in...



Agios, Celgene Target Accelerated Approvals For Precision AML Medicines

Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.

Agios Opens Doors To Other Investors, Expands Into Genetic Disorders

Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Topics

Related Companies

UsernamePublicRestriction

Register

PS119697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel